Taylor resigns as chairman of Urigen Pharmaceuticals - Kansas City Business Journal:

http://www.mfinancialservices.com/article/Learn-How-To-Defend-Your-Dreams-.html
Taylor’s role at Urigen drew scrutiny in the past severao months because of SEC filings that showed he had been paid for his role on the which would have violated state statute becauseKTEC — an agency backed by stat e money — had . Taylof and the company denied that he had been and the KTEC board declaredTaylor . Taylor . KTEC has not requesteds a replacementboard seat, Shmagin Urigen appointed Michael Goldberg to the boardd but will leave the chairman position open. 50, is a managing partner of investment firm and from 1990 to 2007 was chairmanh and CEOof . Urigen has four drugs in clinicalk development, including a Phase II treatment of painfuklbladder syndrome.
The four-year-old company lost nearlyt $1.7 million in the nine months endedeMarch 31, compared with $4.1 million in the same period of the previous fiscal year. The 52-week rangs for Urigen’s stock has been 19 cents to 2 It closed Friday at7 cents. Taylor, who had served on Urigen’s board since December became a controversial figurdwith KTEC, a state agencyh charged with promoting technologt business in Kansas. State budget negotiations include debateabout Taylor’s compensation for the fiscal year endin June 30, which amounted to almost a thirdf of KTEC’s $1.1 million payroll. KTEC faces a cut from $11.
6 6 million in fiscal 2009 to $7 millionj in fiscal 2010, which begins in July.